Main navigation
- Home
- LDL-C lowering
- HDL-C raising
- Well tolerated
- Prescribed in millions of patients
- Initiating CRESTOR treatment
- Safety and tolerability
- Prescribing information
- Person behind the numbers
- Clinical research
- Cardiovascular disease background
- Resources
- References
- Congress reports
- Feedback
- Sitemap
- CRESTOR in your country
CRESTOR Healthcare Professional Site
This website is intended for international health care professionals. US visitors, please visit CRESTOR.com, UK visitors, please visit AstraZeneca UK. Not all products are available in all countries. Product licences differ between countries. Please consult your local prescribing information. Patients or caregivers please visit Patient Health International.
CRESTOR (rosuvastatin) is a statin indicated for the treatment of dyslipidaemia.
The FDA has approved CRESTOR as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol in the United States. CRESTOR is also approved for use in atherosclerosis in Mexico,
Brazil, Colombia, Argentina, Barbados, Bermudas, Jamaica, Ukraine, Hungary,
Philippines and Thailand.
-
Features
- Dyslipidaemia interactive training Listen to the story of Dudley and discover how CRESTOR can improve the lipid profile and manage cardiovascular risk in your patients.
- Publication updates Register for the alert service and receive updates when publications on rosuvastatin are published.
- Efficacy CRESTOR reduces LDL-C by up to 63%
-
Cardiovascular news
-
Jan 5, 2009
:
Progression of atherosclerosis in diabetic patients associated with vessel shrinkage
-
Jan 5, 2009
:
HF etiology predicts outcome following cardiac resynchronization therapy
-
Jan 5, 2009
:
Neuropeptide Y is strong candidate gene for early CAD
-
Jan 5, 2009
:
Progression of atherosclerosis in diabetic patients associated with vessel shrinkage